Document:

ex10_1.htm

EXHIBIT 10.1

 

FOURTH AMENDMENT TO

REVOLVING CREDIT AND SECURITY AGREEMENT

THIS FOURTH AMENDMENT TO REVOLVING CREDIT AND SECURITY AGREEMENT (this “Amendment”), dated as of July 31, 2012, is entered into by and among, IMAGE ENTERTAINMENT, INC., a Delaware corporation (“Image”), IMAGE/MADACY HOME ENTERTAINMENT, LLC, a California limited liability company (“IMHE”) (Image and IMHE, each a “Borrower”, and collectively “Borrowers”), the Lenders signatory hereto and PNC BANK, NATIONAL ASSOCIATION (“PNC”), in its capacity as administrative and collateral agent on behalf and for the benefit of itself and the Lenders (PNC, in such capacity, the “Agent”).  Terms used herein without definition shall have the meanings ascribed to them in the Credit Agreement defined below.

 

RECITALS

 

A.           The Lenders, Agent and Borrowers have previously entered into that Revolving Credit and Security Agreement dated as of June 23, 2011, as amended by that First Amendment to Revolving Credit and Security Agreement dated as of July 13, 2011, that Second Amendment to Revolving Credit and Security Agreement dated as of November 2, 2011 and that Third Amendment to Revolving Credit and Security Agreement dated as of February 29, 2012 (as so amended and as the same may be further amended, modified or supplemented from time to time, the “Credit Agreement”), pursuant to which the Lenders have made certain loans and financial accommodations available to Borrowers.

 

B.            Borrowers have requested that Agent and the Lenders extend the credit enhancements provided in the Third Amendment in connection with the 2012 Transaction.

 

C.            The Lenders, Agent and Borrowers now wish to amend the Credit Agreement on the terms and conditions set forth herein.

 

D.            Borrowers are entering into this Amendment with the understanding and agreement that, except as specifically provided herein, none of Agent’s or any Lender’s rights or remedies as set forth in the Credit Agreement or any Other Document is being waived or modified by the terms of this Amendment.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.             Amendments to Credit Agreement.

 

(a)           Section 1.2 of the Credit Agreement is hereby amended as follows:

 

  

  

  

 

(i)           The definition of “Required Sponsor SBLC Amount” is hereby deleted and replaced in its entirety with the following:

 

“Required Sponsor SBLC Amount” shall mean the lesser of (i) $5,000,000 or (ii) the difference of (x) outstanding Revolving Advances as of September 30, 2012 minus (y) the Receivables Formula Amount plus the Inventory Formula Amount minus the amount of Section 2.1(a)(vi), with the amounts set forth in this clause (y) to be calculated without giving effect to the amendments to subclauses (y) and (z) of clause (q) of the definition of “Eligible Receivables” in the Third Amendment; reduced, in the case of clause (i) only, by any amounts previously drawn pursuant to the Sponsor Standby Letters of Credit delivered to Agent pursuant to Section 8.3(b) of the Credit Agreement (as amended by the First Amendment).  Notwithstanding the foregoing, after October 1, 2012, the Required Sponsor SBLC Amount may be reduced from time to time until January 31, 2013 upon three Business Day’s prior written notice to Agent so long as (A) no Default or Event of Default exists or would otherwise result from such reduction and (B) Undrawn Availability after giving effect to such reduction is not less than $1,000,000.

 

(ii)           The following new definition of “Fourth Amendment” is inserted in proper alphabetical order into Section 1.2 of the Credit Agreement:

 

“Fourth Amendment” means that Fourth Amendment to Revolving Credit and Security Agreement dated as of July 31, 2012, amending this Agreement, among Borrowers, the Lenders and Agent.

 

(b)           Section 2.1 of the Credit Agreement is hereby amended as follows:

 

(i)           The paragraph immediately following Section 2.1(a)(vi) of the Credit Agreement is hereby deleted and replaced in its entirety with the following:

 

The amount derived from (x) the sum of Sections 2.1(a)(i), (ii) and (iii) (provided that for purposes of this clause (x), (1) the sum of the Receivables Formula Amount and the Inventory Formula Amount attributable to Receivables and Inventory of IMHE shall be capped at an aggregate amount of $4,000,000 and (2) the Maximum Sponsor SBLC Amount at any time shall be at least $3,000,000 (and as of the date of the Fourth Amendment is equal to $3,700,000; provided that such amount may be changed upon Borrowers’ request in a writing delivered to the Agent from time to time subject to the Agent’s written confirmation of its approval of other amount, such approval to be at the Agent’s sole discretion); provided further that if the 2012 Transaction shall not be consummated on or prior to September 30, 2012, as determined by Agent in its reasonable discretion, the Maximum Sponsor SBLC Amount shall from and after October 1, 2012 be at least the Required Sponsor SBLC Amount) minus (y) the sum of Sections 2.1(a)(iv) through (vi) at any time, and from time to time shall be referred to as the “Formula Amount.”

 

  

- 2 -

  

 

2.             Agreement Regarding Amendments in Section 1(b)(i) and 1(b)(ii) of the Third Amendment.  Notwithstanding anything herein or in the Third Amendment to the contrary, Borrowers and the Lenders agree that, if the 2012 Transaction is not consummated on or prior to September 30, 2012, as reasonably determined by Agent, the amendments to the Credit Agreement contained in Section 1(b)(i) and (ii) of the Third Amendment as extended by this Fourth Amendment regarding the Availability Block and the eligibility of Broadcast Receivables, respectively, shall no longer be effective and such amended provisions of the Credit Agreement shall automatically revert to the provisions of the Credit Agreement in effect prior to the effectiveness of the Third Amendment.

 

3.             Limited Amendment; Full Force and Effect.  The amendments set forth in Section 1 of this Amendment and the agreement set forth in Section 2 of this Amendment are effective solely for the purposes set forth herein and shall be limited precisely as written and shall not be deemed (a) to be an amendment, consent or waiver of any other term or condition of the Credit Agreement or any Other Documents or of any future failure to comply fully with the requirements of the Credit Agreement or the Other Documents, to prejudice any right or remedy which the Lenders or the Agent may now have or may have in the future under or in connection with the Credit Agreement or the Other Documents or (b) to be a consent to any future amendment, consent or waiver or departure from the terms and conditions of the Credit Agreement or any of the Other Documents.  This Amendment shall be construed in connection with and as part of the Credit Agreement and the Other Documents, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein waived or amended, are hereby ratified and confirmed and shall remain in full force and effect.

 

4.             Effectiveness of this Amendment.  This Amendment shall become effective upon the satisfaction of each of the following conditions:

 

(a)           Amendment.  Receipt by the Agent of this Amendment, fully executed in a sufficient number of counterparts for distribution to all parties.

 

(b)           Sponsor Guarantor Acknowledgement and Agreement.  Receipt by the Agent of the fully executed Sponsor Guarantor Acknowledgement and Agreement.

 

(c)           Accommodation Fee.  Receipt by the Agent, for the account of PNC as the sole Lender, of an accommodation fee equal to $16,667, payable in cash, which fee will be fully earned and non-refundable once received.

 

(d)           Representations and Warranties.  The representations and warranties set forth in Section 5 hereof shall be true and correct.

 

(e)           Other Required Documentation.  All other documents and legal matters in connection with the transactions contemplated by this Amendment shall have been delivered or executed or recorded, as required by Agent.

 

5.             Representations and Warranties.  Borrower represents and warrants as follows:

 

  

- 3 -

  

 

(a)           Authority.  Each Borrower has the full power, authority and legal right to enter into this Amendment and the Other Documents (as amended or modified hereby) and to perform all of its respective obligations hereunder and thereunder.  The execution, delivery and performance of this Amendment by each Borrower:  (i) have been duly authorized by all necessary corporate or limited liability company action, as applicable; (ii) are not in contravention of law or the terms of such Borrower’s by-laws, certificate of incorporation, operating agreement, articles of organization or other applicable documents relating to such Borrower’s formation or to the conduct of such Borrower’s business or of any material agreement or undertaking to which such Borrower is a party or by which such Borrower is bound; (iii) will not conflict with or violate any law or regulation, or any judgment, order or decree of any Governmental Body; and (iv) will not require the Consent of any Governmental Body or any other Person.

 

(b)           Enforceability.  This Amendment has been duly executed and delivered by each Borrower and no other corporate or limited liability company proceedings are necessary to consummate such transactions.  This Amendment (as amended or modified hereby) and each Other Document is the legal, valid and binding obligation of each Borrower, enforceable against each Borrower in accordance with its terms, and is in full force and effect, except as such enforceability may be limited by any applicable bankruptcy, insolvency, moratorium or similar laws affecting creditors’ rights generally.

 

(c)           Representations and Warranties.  The representations and warranties made by any Borrower in or pursuant to this Amendment, each Other Document and any related agreements to which it is a party, and each of the representations and warranties contained in any certificate, document or financial or other statement furnished at any time under or in connection with this Amendment, the Other Documents or any related agreement shall be true and correct in all material respects on and as of such date as if made on and as of such date, unless made specifically as of an earlier date, in which case they shall be true and correct in all material respects as of such earlier date.

 

(d)           No Default.  No event has occurred and is continuing that constitutes a Default or an Event of Default.

 

6.             Governing Law.  This Amendment shall be governed by and construed in accordance with the laws of the State of New York applied to contracts to be performed wholly within the State of New York, without regard to principals of conflicts of law other than New York General Obligations Law 5-1401 and 5-1402.

 

7.             Counterparts; Facsimile Signatures.  This Amendment may be executed in any number of and by different parties hereto on separate counterparts, all of which, when so executed, shall be deemed an original, but all such counterparts shall constitute one and the same agreement.  Any signature delivered by a party by facsimile or other similar form of electronic transmission shall be deemed to be an original signature hereto.

 

  

- 4 -

  

 

8.             Reference to and Effect on the Other Documents.

 

(a)           Upon and after the effectiveness of this Amendment, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, and each reference in the Other Documents to “the Credit Agreement”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified and amended hereby.

 

(b)           Except as specifically amended above, the Credit Agreement and all Other Documents, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of Borrower to Agent and the Lenders.

 

(c)           The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Agent and/or the Lenders under any of the Other Documents, nor constitute a waiver of any provision of any of the Other Documents.

 

(d)           To the extent that any terms and conditions in any of the Other Documents shall contradict or be in conflict with any terms or conditions of the Credit Agreement, after giving effect to this Amendment, such terms and conditions are hereby deemed modified or amended accordingly to reflect the terms and conditions of the Credit Agreement as modified or amended hereby.

 

9.             Integration.  This Amendment, together with the Other Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.

 

10.           Severability.  If any part of this Amendment is contrary to, prohibited by, or deemed invalid under Applicable Laws, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder hereof shall not be invalidated thereby and shall be given effect so far as possible.

 

[signature pages follow]

 

  

- 5 -

  

 

IN WITNESS WHEREOF, the parties have entered into this Amendment as of the date first above written.

 

	 	
IMAGE ENTERTAINMENT, INC.

	 
	 	 	 
	 	
By: 

	/s/ John Avagliano	 
	 	 	Name: 	John Avagliano   	 
	 	 	Title:	COO/CFO  	 

 

	 	
IMAGE/MADACY HOME ENTERTAINMENT, LLC

	 
	 	 	 
	 	
By: 

	/s/ John Avagliano	 
	 	 	Name: 	John Avagliano   	 
	 	 	Title:	COO/CFO  	 

  

  

  

 

	 	PNC BANK, NATIONAL ASSOCIATION,	 
	 	as Agent as a Lender	 
	 	 	 	 
	 	
By: 

	/s/ Steve C. Roberts	 
	 	 	
Steve C. Roberts

	 
	 	 	
Vice Presidentex10_4.htm

EXHIBIT 10.4

 

RESEARCH AND DEVELOPMENT SERVICES AGREEMENT

This Agreement, is made and entered into on June 22, 2012 (“Effective Date”), by and between Discovery Laboratories, Inc., having a place of business at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (“Discovery”) and Battelle Memorial Institute, through its Corporate Operations, having a place of business at 505 King Avenue, Columbus, Ohio 43201 (“Battelle”) individually referred to as “Party” or collectively referred to as “Parties.”

WHEREAS, Discovery desires to have Battelle support the research and development of Discovery’s Clinical Capillary Aerosol Generator (CAG), initially for use in the AEROSURF® Neonatal (NN) program for respiratory distress syndrome (RDS) (“Project Device”), and Battelle desires to perform such services.

NOW THEREFORE, in consideration of the mutual covenants and agreements contained herein, Battelle agrees to provide to Discovery technical and research services substantially in accordance with Battelle’s Proposal No. OPP106184 (the “Project”) attached hereto and incorporated herein by reference, under the following terms and conditions:

	
1.

	
Term, Acceptance of Proposal(s)

The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect for a period of two (2) years unless earlier terminated as provided in Section 11. Discovery’s acceptance of Battelle’s Proposal(s) and the commencement and timeline of services thereunder shall be as set forth in the respective Proposal(s).

	
2.

	
Payment

2.1.        Payment Terms. Discovery agrees to pay Battelle’s charges for labor services and other expenses for performance of the Project, as set forth in separately executed Proposal(s). Unless otherwise specified in the Proposal(s), Battelle will invoice Discovery on a monthly basis, and Discovery shall pay such invoice, within thirty (30) days of the invoice date. Discovery will not be required to reimburse, and Battelle shall not be required to incur any charges in excess of the estimate stated above, unless mutually agreed upon in writing. [ *** ]. Discovery shall submit invoicing instructions to Battelle in accordance with Exhibit A; and Battelle shall invoice Discovery in a form similar to Exhibit B. [ *** ].

2.2.        Taxes. Compensation, as set forth in the Proposal(s), shall include current federal, state and local taxes levied in the United States or on the wages paid to Battelle U.S. employees. Any other present or future taxes, duties, tariffs, fees or other charges, including but not limited to excise, import, purchase, sales, use, turnover, added value, consular, gross receipts, gross wages or other assessments imposed by the government of any other country or subdivision thereof shall be the obligation of Discovery. In the event sales tax applies (e.g., prototypes), Battelle will waive such tax if Discovery furnishes a valid tax exemption certificate for the state in which product is shipped. Any such amounts paid by Battelle shall be added to the estimated amount above and paid by Discovery within thirty (30) days of the date of invoice. Payments shall be made in United States Dollars.

	
3.

	
Intellectual Property

3.1.        Discovery Inventions. [ *** ] (2) “Discovery Invention” is defined as (i) Discovery’s proprietary aerosol technologies including the devices employed in producing aerosol (currently CAG devices and AFECTAIR® brand devices) that are used in performance of the Project, [ *** ], and (iv) Discovery’s pulmonary surfactant used in performance of the Project, alone or in combination with other compounds. For a period of [ *** ] after the termination or expiration of the Project and at Discovery’s request and expense, Battelle will provide Discovery with reasonable assistance to obtain patents on Discovery Inventions and to execute all necessary declarations, affidavits and assignments.

  

Page 1 of 10

  

 

3.2.        Battelle Inventions. Inventions made in performance of the Project [ *** ] (a “Battelle Invention”) are outside the scope of the Project and are retained by Battelle.  To the extent that practicing a Battelle Invention interferes with Discovery’s freedom to operate while practicing a Discovery Invention, Battelle hereby provides Discovery a [ *** ] license to use such Battelle Invention [ *** ].

3.3.        Non-Infringement Representation. Discovery represents that to the best of Discovery’s knowledge there is no patent issued to a third party as of the Effective Date of this Agreement that would be infringed by the manufacture, use, or sale of CAG as contemplated by this Agreement. [ *** ].

3.4.        No License. No license to the other Party, under any trademark, patent or copyright is either granted or implied by conveying information to that Party. None of the information that may be submitted or exchanged by the respective parties shall constitute any representation, warranty, assurance, guarantee, or inducement by either Party to the other with respect to infringement of trademarks, patents, copyrights or any right of privacy, or other rights of third persons.

3.5.        Work Product.  For the avoidance of doubt, Discovery shall own [ *** ] outputs and results generated in the performance of the Project, except for such reports, data and other outputs and results that relate to Battelle Inventions.

	
4.

	
No Endorsement: Public Announcement

Discovery agrees that it will not use or imply Battelle’s name or use Battelle’s Reports for endorsement of Discovery’s products or fund raising without the prior written approval of an officer of Battelle; however, Discovery may use Battelle’s name or use Battelle’s reports for regulatory reporting without the prior written approval of an officer of Battelle. For the avoidance of doubt, Discovery may use the content of Battelle Reports for commercially reasonable purposes. Battelle agrees that it will not use or imply Discovery’s name or use Discovery’s name for any purpose without the prior written approval of an officer of Discovery. Notwithstanding the foregoing, if Discovery concludes in good faith that it is necessary or appropriate to file or describe this Agreement or any related agreements or documents, or provide other notification thereof in a periodic or other report to be filed with the Securities and Exchange Commission or other federal, state or international regulatory authority (“Regulatory Authority”), Discovery at its own expense shall request confidential treatment of sensitive provisions of this Agreement, provided such confidential treatment is reasonably available to Discovery. The Parties shall promptly inform each other in the event of any activities or inquiries of any such Regulatory Authority relating to this Agreement, and shall reasonably cooperate to respond to any request for further information therefrom on a timely basis.

	
5.

	
Confidentiality

5.1.        Confidentiality Agreement. The Mutual Confidential Disclosure Agreement between Discovery and Battelle effective December 3, 2010, and its subsequent amendments prior to this Agreement, hereinafter the “CDA”) continues in full force and effect and shall govern the Parties’ conduct and handling of Confidential Information under this Agreement. The Parties hereby agree to amend the CDA to extend the term thereof through the date that is one year after the expiration or earlier termination of this Agreement.

  

Page 2 of 10

  

 

5.2.        Confidential Information. Discovery has provided Battelle with certain information and data related to the Project (the “Confidential Information,” as such term is further defined in the CDA). The Parties agree that any and all information, data and device developed in performance of the Project, including Discovery Inventions and Battelle Inventions, constitute Confidential Information and shall be protected in accordance with the terms and conditions of the CDA. Battelle agrees not to disclose the specific results of the Project as may be embodied in reports and correspondence transmitted to Discovery, and not available to the public generally, without Discovery’s written consent, except as required by law. If Battelle wishes to use any results, data or information generated during the performance of the Project for purposes of protecting or publicly disclosing Battelle Inventions (“Disclosure”), Battelle shall seek Discovery’s written authorization and shall provide Discovery with a written notice and detailed description of the information intended for inclusion in the Disclosure at least ninety (90) days in advance of the Disclosure, or such reasonable time acceptable to Discovery, to allow time for Discovery to make arrangements necessary, or to request that Battelle make reductions or modifications of such results, data or information, to protect Discovery Inventions.

5.3.        Battelle Activities. [ *** ].

	
6.

	
Nature of Services

Discovery agrees that Battelle is an independent contractor and specifically acknowledges that Battelle is a service provider, not a manufacturer, distributor or supplier. Discovery retains all final decision making authority and all responsibility for the formulation, design, manufacture, assembly, packaging, marketing, distribution and sale of Discovery’s products, including, without limitation, product labeling, warnings, instructions to users, reporting and for obtaining any governmental or other pre- or post-market approvals (FDA and otherwise), certifications, registrations, licenses, or permits.

	
7.

	
Warranties; Limitation of Liability

7.1.        Warranties. Battelle represents and warrants that it will use commercially reasonable efforts to provide a high standard of professional service. However, Battelle, as a provider of such services, cannot guarantee success, thus Battelle MAKES NO WARRANTY OR GUARANTEE, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE OR MERCHANTABILITY, FOR ANY REPORT, DESIGN, ITEM, SERVICE OR OTHER RESULT TO BE DELIVERED UNDER THIS AGREEMENT.

7.2.        Limitations. Discovery assumes responsibility for its use, misuse, or inability to use the Project results.  Except as necessary to satisfy Third Party Claims (as defined in Section 8) indemnified hereunder, [ *** ], Battelle’s total liability to Discovery and all liabilities arising out of or related to this Agreement [ *** ]. Except for a breach of its confidentiality obligations hereunder and as set forth in the CDA, neither Party shall be liable to the other Party for any indirect, incidental, consequential, special, punitive or exemplary damages in connection with this Agreement or the Project, however caused, under any theory of liability. [ *** ].

	
8.

	
Indemnities.

8.1.        Third Party Claims. Each of the Parties shall defend, indemnify and hold harmless the other Party, its affiliates and its and their respective directors, officers, employees, consultants, contractors, representatives and agents (collectively, the “Indemnified Parties”) from and against any and all losses, costs, damages, fees, liabilities, or expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) incurred in connection with any third party claim, action or proceeding (a “Third Party Claim”) to the extent caused by:

  

Page 3 of 10

  

 

8.1.1.       any material breach by the indemnifying Party of any of its representations, warranties, covenants or obligations pursuant to this Agreement; and

8.1.2.       any negligence, recklessness, willful misconduct or wrongful intentional acts or omissions of the indemnifying Party, its affiliates, or their officers, directors, employees, contractors, consultants, agents, representatives, or sublicensees in the exercise of any of the indemnifying Party’s rights or the performance of any of the indemnifying Party’s obligations under this Agreement.

8.2.        Additional Discovery Indemnities. In addition to the indemnity set forth in Section 8.1 above, Discovery shall defend, indemnify and hold harmless Battelle, its affiliates and its and their respective directors, officers, employees, consultants, contractors, representatives and agents from and against any and all Losses incurred in connection with any Third Party Claim that [ *** ].

8.3.        Product Liability. Notwithstanding the provisions of Sections 8.1, Discovery shall defend, indemnify and hold harmless Battelle, its affiliates and its and their respective directors, officers, employees, consultants, contractors, representatives and agents from and against any and all Losses incurred in connection with any Third Party Claims arising out of or relating to the commercialization, marketing, sale, use, handling, manufacture and/or storage of any Project Device, including any claims that involve death or bodily injury (or allegations thereof) to any individual.

8.4.        Indemnification Procedures. In the event that an Indemnified Party is entitled to indemnification under this Agreement, such Indemnified Party shall promptly notify the indemnifying Party in writing of the claim (in reasonable detail); provided, however, that failure to give such notification shall not affect the indemnification to be provided hereunder except to the extent the indemnifying Party shall have been actually prejudiced as a result of such failure. As a condition to indemnification under this Agreement, the indemnifying Party, in its discretion and at its expense, may manage and control the defense of the claim and its settlement. The Indemnified Parties shall provide the indemnifying Party with reasonable assistance and cooperation and all material relevant information to support the defense of any indemnified claim, and the indemnifying Party shall reimburse the Indemnified Parties for their reasonable out-of-pocket expense incurred in connection with such assistance and cooperation. The indemnifying Party shall not accept any settlement which imposes liability not covered by the indemnification provided under this Agreement or imposes any obligation on, or otherwise adversely affects, the Indemnified Parties without the prior written consent of the affected Indemnified Parties. The indemnifying Party shall have no obligation to indemnify the Indemnified Parties in connection with any settlement made without the indemnifying Party’s written consent. Except for such assistance and cooperation as may reasonably be requested by the indemnifying Party, nothing contained in this section shall require any Indemnified Party to take any action in its own name in defending any claim, action or proceedings; however, an Indemnified Party, at its option and expense, may review and comment on the defense of any claim through its own counsel. If (i) in the opinion of counsel for an Indemnified Party, representation of such Indemnified Party by the counsel retained by the indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other Party represented by such counsel in such proceedings, or (ii) the named parties to any such proceeding (including the impleaded parties) include both the indemnifying Party and the Indemnified Party, and representation of both Parties by the same counsel would be inappropriate in the opinion of the Indemnified Party’s counsel due to actual or potential differing interests between them; in any such case, one firm of attorneys separate from the indemnifying Party’s counsel may be retained to represent the Indemnified Parties with respect to which a conflict exists at the indemnifying Party’s expense. As the Parties intend complete indemnification, all reasonable attorneys’ fees and expenses incurred by an Indemnified Party in connection with enforcement of this Section 8 shall also be reimbursed by the indemnifying Party.

  

Page 4 of 10

  

 

	
9.

	
Insurance

9.1.        Product Liability Coverage. If any Project Device developed under this Agreement are used by Discovery in clinical trial(s), prior to the first activity involving human subjects, Discovery, its successor in interest or the then owner of the Project Device, agrees to maintain adequate clinical trials liability insurance coverage in amounts customary and prudent for a responsible entity in its industry in light of the nature of its products. Such insurance shall cover any Discovery products that may be developed in whole or in part based on Battelle’s work under this Agreement and used in a clinical trial.

9.2.        Commercial Activities. Prior to the commercial sale of any Project Device, Discovery, its successor in interest or the then owner of the Project Device, shall maintain adequate product liability insurance coverage in amounts customary and prudent for a responsible entity in its industry in light of the nature of its product(s). Such insurance shall cover any Discovery products that may be developed in whole or in part based on Battelle’s work under this Agreement.

9.3.        Insurers. Discovery shall use reasonable commercial efforts to maintain coverage with insurance companies that [ *** ], provided that such insurance is available at commercially reasonable costs.  Discovery (or its agents or sublicensees) shall maintain products liability coverage related to the Project Device in all territories (on a country-by-country basis) in which the Device is commercially available and shall name Battelle as an additional insured. Discovery shall maintain such insurance throughout the period of any activity involving human subjects and, if such insurance is on a claims-made basis, for [ *** ] following completion of such activity. Discovery, its successor in interest or the then owner of the Project Device shall provide a certificate of insurance to Battelle evidencing such coverage prior to the first administration to a human subject of the drug product aerosolized using the Project Device. Such certificate shall provide for at least thirty (30) days prior notice to Battelle of any cancellation, non-renewal, or relevant reduction in coverage.

	
10.

	
Force Majeure

Neither Discovery nor Battelle shall be liable in any way for failure to perform any provision of this Agreement (except payment of monetary obligations) if such failure is caused by any law, rule, or regulation, or any cause beyond the control of the Party in default.

	
11.

	
Termination

11.1.           Early Termination. Either Party shall have the right to terminate this Agreement upon fifteen (15) days’ written notice for any good-faith basis; provided, however, that Battelle shall not have the right to terminate this Agreement until it has substantially completed the then-current phase of the Project, determined by reference to the Project Plan. In the event of early termination, Battelle agrees to provide Discovery with all reports, materials, or other deliverable items available as of the effective date of the termination, provided that Discovery is not in default of its payment obligations under this Agreement. In any event, Discovery agrees to pay all charges incurred or committed by Battelle, including reasonable costs of termination, within thirty (30) days of receipt of a final invoice.

11.2.           Discovery Material Breach. Notwithstanding the foregoing, Battelle shall have the right to terminate this Agreement upon fifteen (15) days’ written notice to Discovery in the event that Discovery is in material breach (which includes but is not limited to failure to make payment of undisputed amounts under this Agreement), and such breach is not cured within such fifteen day period.

	
12.

	
Regulatory Matters

12.1.           General; Quality System. Prior to initiation of development activities as set forth in Phase 2 OPP106184 of this Agreement, Discovery and Battelle shall enter into a Quality Agreement (“Quality Agreement”) in such form as is acceptable to both Parties. In conducting activities under this Agreement, each Party shall comply in all material respects with all applicable laws and in accordance with the Quality Agreement, including without limitation, U.S. Food and Drug Administration (“FDA”) current Good Manufacturing Practice (“cGMP”) requirements set forth in the FDA Quality System Regulations (“QSR”) applicable to the design and production of clinical devices under Investigational Device Exemptions , 21 CFR 812. Each Party shall bear its own costs and expenses related to QSR compliance. The termination or expiration of this Agreement shall not relieve either Party of its responsibility to comply in all material respects with any applicable regulatory requirements associated with development and use of the Project Device.

  

Page 5 of 10

  

 

12.2.           FDA Debarment Certification. Battelle represents and warrants that, after due inquiry, it has not and will not knowingly employ, contract with or retain any person directly or indirectly to perform services under this Agreement, if such person is debarred by the FDA under 21 USC 335a(k) of the FDA Act or a regulator in the EU under similar laws. Upon written request from Discovery, Battelle shall within five (5) business days confirm in writing that it has complied with the foregoing obligation.

	
13.

	
U.S. Export Control

Discovery agrees not to export or re-export any goods, services, or information obtained from Battelle without first obtaining an export license, if required by law.

	
14.

	
Client Furnished Materials

Any device, property, equipment, materials or other tangible property furnished by Discovery for use on this Project shall remain the property of Discovery unless otherwise agreed in writing, and will be governed by a separate agreement. [ *** ]. Discovery will cooperate in providing any operation instructions to Battelle upon request and Battelle may reasonably rely on the information so provided. Battelle shall provide such information as Discovery may reasonable request in connection with Discovery’s efforts to secure casualty and other insurance covering any such device, property, equipment, materials or other tangible property furnished by Discovery to Battelle in connection with the Project.

	
15.

	
Entire Agreement

This Agreement, including any related agreement provided hereunder (including, but not limited to, the Quality Agreement), the Proposal, and the CDA incorporated herein, represents the entire agreement of the parties and terminates and supersedes any prior discussions or understandings, whether written or oral, relating to the subject matter hereof. This Agreement may be modified or amended only by mutual agreement in writing. No course of dealing, usage of trade, waiver, or non-enforcement shall be construed to modify or otherwise alter the terms and conditions of this Agreement. In the event of any conflict or inconsistency between these terms and conditions and the Proposal, these terms and conditions shall control.

	
16.

	
Dispute Resolution

16.1.           Executive Negotiation. In the event of any material dispute, difference, claim, action, demand, request, investigation, controversy, threat or other question arising out of or relating to the interpretation of any provisions of this Agreement or the failure of any Party to perform or comply with any obligations or conditions applicable to such Party pursuant to this Agreement (a “Dispute”) shall be settled in accordance with the provisions of this Section 16.  In the event of such a Dispute, written notice of the dispute must be provided to the other Party within thirty (30) days of the events giving rise to the Dispute.  The Parties shall each designate one member of Senior Management to represent it in a meeting to resolve the Dispute.  The designated Senior Managers shall negotiate in good faith to achieve a resolution to the Dispute referred to them, within Thirty (30) days after such notice is received. If the Parties are unable to resolve a Dispute within the referenced time frame, the Parties shall each designate a Senior Executive to represent it in a meeting to resolve the Dispute.  The Senior Executives shall endeavor to resolve the Dispute through negotiation.  If a Dispute is not resolved during Senior Executive negotiation within sixty (60) days, either Party may refer such Dispute to final and binding arbitration by sending written notice of such election to the other Party clearly marked “Arbitration Demand,” whereupon such Dispute shall be arbitrated in accordance with this Section.

  

Page 6 of 10

  

 

16.2.           Arbitration Procedures.  Any arbitration shall be conducted under the then-current expedited procedures applicable to the then-current Commercial Arbitration Rules of the AAA in accordance with this Section 16.2. The arbitration of any Dispute shall be kept confidential and shall be filed with the office of the AAA located in Wilmington, Delaware, or such other AAA office as the Parties may agree. The arbitration shall be conducted by three arbitrators, one appointed by each of Battelle and Discovery and the third selected by the first two appointed arbitrators.  Each arbitrator shall be a person with relevant experience in the medical device development field.  Battelle and Discovery must make their respective arbitrator appointments within ten (10) business days of receipt of an Arbitration Demand.  Such appointed arbitrators shall select the third arbitrator within ten (10) business days after the second arbitrator has been appointed.  Battelle and Discovery shall instruct such arbitrators to render a determination of any such Dispute within sixty (60) days after the appointment of the third arbitrator. All Disputes shall be resolved by submission of documents unless the arbitration panel determines that an oral hearing is necessary. The decision of the arbitrators with respect to any Dispute shall be in writing and state the findings, facts and conclusions of law upon which the decision is based.  Any such decision and award rendered by the arbitrators shall be final and binding upon the Parties.  Judgment upon any award rendered may be entered in any court having jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be. Each Party submits itself to the jurisdiction of any such court for the entry and enforcement to judgment with respect to the decision of the arbitrators hereunder.  The arbitrators shall have the power to grant all legal and equitable remedies except specific performance and award compensatory damages provided by applicable law, but shall not have the power or authority to award punitive damages. No Party shall seek punitive damages or specific performance in relation to any matter relating to this Agreement in any other forum, provided that the foregoing does not preclude suits or limit damages associated with equitable relief related to a breach of confidentiality obligations under this Agreement or the CDA. Each Party shall pay its own expenses of arbitration, and the expenses of the arbitrators shall be equally shared between Battelle and Discovery unless the arbitrators assess all or any part of the arbitration expenses of a Party (including reasonable attorneys’ fees) as part of their award against the other Party.

	
17.

	
Applicable Law

This Agreement shall be governed by and construed in accordance with the laws of and enforced within the jurisdiction of the State of Delaware without regard to the principles of conflict of laws.

	
18.

	
Survival

Sections 3, 4, 5, 7, 8, 9, and 12 through 19 of this Agreement shall survive the termination or expiration of this Agreement.

	
19.

	
Miscellaneous

This Agreement may not be assigned in whole or in part without the prior written approval of both parties. Notwithstanding the foregoing, without the prior written approval of Battelle, Discovery may assign or otherwise transfer (including by operation of law) this Agreement in connection with a corporate transaction, including, without limitation, merger, combination, sale of stock, sale of assets, change of control, or other similar transaction, provided that the assignee assumes all of the obligations under this Agreement; however, no such assignment shall be made to an assignee if the assignee is on the Excluded Parties List (https://www.epls.gov/) or subject to an Executive Order (http://www.whitehouse.gov/briefing-room/presidential-actions/executive-orders) prohibiting transactions with the assignee. In any event, however, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by and against the successors, assigns, and transferees of the parties. If any part of this Agreement shall be held invalid or unenforceable, such invalidity and unenforceability shall not affect any other part of this Agreement. Captions used as headings in this Agreement are for convenience only and are not to be construed as a substantive part of this Agreement.

  

Page 7 of 10

  

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representative as of the Effective Date.

	 	
 

DISCOVERY LABORATORIES, INC.

	 	 	
 

BATTELLE MEMORIAL INSTITUTE

Corporate Operations

 

	 
	By	/s/ Mary B. Templeton	 	By 	/s/ Laura E. Fillman	 
	 	 	 	 	 	 
	Name	
 Mary B. Templeton

	 	Name 	
Laura E. Fillman

 

	 
	 	
 

	 	 	 	 
	
Title 

	
Senior Vice President, General Counsel

	 	
Title

	
Contracting Officer

 

	 
	 	 	 	 	 	 
	Date	
June 22, 2012

	 	Date	

June 22, 2012

	 
	 	 	 	 	 	 

 

  

Page 8 of 10

  

 

Exhibit A

Invoicing Instructions

 

	 	 	
 

Battelle Memorial Institute

Corporate Operations

Proposal/Agreement No. OPP106184

 

 

Invoicing Instructions

 

 

Invoice(s) should be sent to the attention of:

 

 

(Name)

 

 

  

(Address)

 

 

  

(Reference: Purchase Order Number, OPP106184)

 

 

  

(Phone Number)

 

 

 

If additional invoices are required, please provide the following information:

 

	 	 
	 	 	Name	Address	Number of Invoices    	Other	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	
 

Please complete this form and return with the signed Agreement

 

 

	 	 

 

 

  

Page 9 of 10

  

 

 

 

Exhibit B

[ *** ]

 

  Page 10 of 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]